Welcome to our dedicated page for INVO Fertility news (Ticker: IVF), a resource for investors and traders seeking the latest updates and insights on INVO Fertility stock.
INVO Fertility, Inc. (Nasdaq: IVF) generates news as a healthcare services fertility company focused on assisted reproductive technology (ART), clinic operations, and its INVOcell-enabled intravaginal culture (IVC) procedure. The news flow around IVF often reflects developments in its fertility clinic network, financing activities, and technology initiatives that support its mission to expand access to fertility care.
Investors and observers following IVF news can expect regular updates on clinic performance and growth, including revenue trends from its INVO Centers and IVF clinic, as well as commentary on organic growth drivers such as patient volume, telehealth expansion, and service offerings at locations like Wisconsin Fertility Institute. Earnings-related press releases have highlighted clinic revenue, product revenue from INVOcell, and adjusted EBITDA metrics, along with management’s narrative on operational progress.
Another key category of news involves acquisitions and strategic agreements. INVO Fertility has reported the acquisition of Wisconsin Fertility Institute and the signing of a definitive asset purchase agreement to acquire the non-clinical assets of Family Beginnings, a fertility clinic in Indiana, through its subsidiary INVO Centers LLC. Such announcements provide insight into the company’s efforts to build a broader network of fertility centers across the United States.
News items also cover capital markets and corporate actions, including private placements of common stock and warrants, registration statements on Form S-1 for resale of securities, and corporate actions such as the 1-for-8 reverse stock split effective November 28, 2025. These updates help investors understand changes in the company’s capital structure and financing arrangements.
Finally, technology and operational updates feature in IVF news, such as the partnership with Heidi Health to deploy an AI-powered scribe platform at Wisconsin Fertility Institute, telehealth launches, and patent developments for a modified INVOcell device. For a consolidated view of these developments, this news page offers a centralized feed of INVO Fertility’s latest press releases and related disclosures.
INVO Fertility (Nasdaq: IVF) closed its acquisition of Family Beginnings, a Midwest fertility clinic, on Feb 19, 2026 for a $760,000 combined purchase price paid in cash and preferred stock. Family Beginnings reported ~$1.0M revenue and ~$0.2M net income for the nine months ended Sept 30, 2025, representing about 18% of INVO's clinic revenue for that period.
The clinic’s medical leadership and care teams remain in place under a multi-year agreement with James Donahue, M.D., and INVO intends to provide operational support and technology investment to expand patient access.
INVO Fertility (Nasdaq: IVF) announced issuance of U.S. Patent No. 12,544,204 B2 effective February 10, 2026, covering a modified INVOcell device design. The patent extends intellectual property protection for the INVOcell intravaginal culture system through 2040. The device has prior FDA clearances in 2015 and a 2023 labeling update.
INVO Fertility (Nasdaq: IVF) CEO Steve Shum issued a shareholder letter outlining operational progress, a strengthened balance sheet, and a dual growth strategy of organic initiatives plus clinic acquisitions. The company operates three profitable clinics, is nearing a fourth-clinic acquisition in Indianapolis, and reports a combined pro forma annualized clinic revenue run rate of approximately $9 million.
Management cites a January 2026 warrant inducement priced at $1.59, simplified capital structure, and expectations for strong growth in 2026 driven by clinic expansion and organic volume gains.
INVO Fertility (NASDAQ: IVF) entered a warrant inducement agreement to lower the exercise price of December 2025 warrants to $1.59 and has an investor agreeing to immediately exercise warrants to buy 4,733,728 shares, generating approximately $7.5 million gross proceeds before fees.
The company will issue 9,467,456 new unregistered warrants at $1.59 per share, subject to shareholder approval, and expects to close the exercise on or about January 30, 2026, subject to customary conditions.
INVO Fertility (Nasdaq: IVF) will participate in a webcast fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026. The live webcast begins at 3:00 p.m. ET and will be available at the conference page https://lythampartners.com/hc2026/ivf. A replay will be accessible at the same link after the event. The company focuses on establishing, acquiring, and operating fertility clinics and related technologies.
INVO Fertility (Nasdaq: IVF) announced an executive realignment effective Dec. 30, 2025 to support its clinic-acquisition growth strategy. Terah Krigsvold, controller since Dec. 2020, is appointed chief financial officer, replacing Andrea Goren. Andrea Goren, CFO since July 2021, becomes chief business officer and CEO of INVO Centers LLC, the company's wholly owned clinic subsidiary, to lead acquisitions and new clinic launches. Management says the move preserves finance continuity while shifting Andrea to focus on growth and transactions. The release notes Andrea has worked on approximately $1 billion of financing and acquisition deals in his career.
INVO Fertility (Nasdaq: IVF) signed a definitive purchase agreement to acquire Family Beginnings, a fertility clinic serving Indiana and the Midwest, advancing a previously announced intent from Nov 27, 2025.
Key terms: purchase price $750,000 for non-clinical assets, $350,000 cash at closing (subject to $150,000 holdback), and $400,000 in Series D non-voting convertible preferred stock. Family Beginnings reported $1.2M revenue and $0.2M net income for the trailing 12 months ended Sept 30, 2025. Closing expected no later than Feb 27, 2026. Dr. James Donahue will continue to lead under a three-year agreement.
INVO Fertility (NASDAQ: IVF) announced a private placement priced at-the-market under Nasdaq rules to a single institutional investor on Dec 2, 2025. The company agreed to sell 2,366,864 shares (or pre-funded warrants) plus warrants to purchase up to 4,733,728 shares at a combined effective price of $1.69 per share plus accompanying warrants. Gross proceeds are estimated at approximately $4.0 million before placement agent fees and expenses. Warrants carry a $1.69 exercise price, will be exercisable upon shareholder approval, and expire five years after such approval. Closing is expected on or about Dec 3, 2025, subject to customary conditions; Maxim Group is sole placement agent. The company will file a resale registration statement with the SEC.
INVO Fertility (Nasdaq: IVF) announced on November 28, 2025 its intent to acquire Family Beginnings, a fertility clinic based in Indianapolis that serves patients across Indiana and the Midwest. This would be INVO's second acquisition after Wisconsin Fertility Institute in 2023 and aligns with its strategy to build a nationwide clinic network.
Family Beginnings offers IVF, INVOcell (IVC), IUI, third-party reproduction, fertility preservation, diagnostic testing, and patient support. Management said a term sheet was executed "over a month ago," and the deal remains subject to customary due diligence, definitive purchase agreements, closing conditions, and any required regulatory approvals.
INVO Fertility (NASDAQ: IVF) announced a 1-for-8 reverse stock split effective at 12:01 a.m. ET on November 28, 2025. Commencing with the market open on November 28, 2025, the common stock will trade on a post-split basis under the same symbol IVF.
As a result of the reverse split every eight shares will be exchanged for one share, fractional shares will be rounded up to the next whole share, and the company will have approximately 1,891,151 shares issued and outstanding after the split. The CUSIP will change to 44984F807, and authorized common shares will be adjusted to 6,250,000 after the effective time.